Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcoma.
Ringwalt EM, Currier MA, Glaspell AM, Chen CY, Cannon MV, Cam M, Gross AC, Gust M, Wang PY, Boon L, Biederman LE, Schwarz E, Rajappa P, Lee DA, Mardis ER, Carson WE, Roberts RD, Cripe TP. Ringwalt EM, et al. Mol Ther Oncol. 2024 Sep 26;32(4):200886. doi: 10.1016/j.omton.2024.200886. eCollection 2024 Dec 19. Mol Ther Oncol. 2024. PMID: 39492947 Free PMC article.
Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors.
Paudel SN, Hutzen BJ, Miller KE, Garfinkle EAR, Chen CY, Wang PY, Glaspell AM, Currier MA, Ringwalt EM, Boon L, Mardis ER, Cairo MS, Ratner N, Dodd RD, Cassady KA, Cripe TP. Paudel SN, et al. Among authors: ringwalt em. Front Immunol. 2024 Jun 25;15:1384623. doi: 10.3389/fimmu.2024.1384623. eCollection 2024. Front Immunol. 2024. PMID: 39044819 Free PMC article.
Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors.
Paudel SN, Hutzen BJ, Miller KE, Garfinkle EAR, Chen CY, Wang PY, Glaspell AM, Currier MA, Ringwalt EM, Boon L, Mardis ER, Cairo MS, Ratner N, Dodd RD, Cassady KA, Cripe TP. Paudel SN, et al. Among authors: ringwalt em. Front Immunol. 2024 Jul 9;15:1456897. doi: 10.3389/fimmu.2024.1456897. eCollection 2024. Front Immunol. 2024. PMID: 39044814 Free PMC article.
Progress in sarcomas: Highlights from the 2023 annual meetingof the Connective Tissue Oncology Society.
Cripe TP, Roberts RD, Chandler DS, Setty BA, Chen S, Shenoy A, Venkataramany AS, Ringwalt EM, Scharschmidt T, Utset-Ward T, Konieczkowski DJ, Grignol VP, Beane JD, Ruff SM, Pollock RE. Cripe TP, et al. Among authors: ringwalt em. Mol Ther Oncol. 2024 Mar 2;32(1):200779. doi: 10.1016/j.omton.2024.200779. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596308 Free PMC article. No abstract available.
Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma.
Ringwalt EM, Currier MA, Glaspell AM, Chen CY, Cannon MV, Cam M, Gross AC, Gust M, Wang PY, Boon L, Biederman LE, Schwarz E, Rajappa P, Lee DA, Mardis ER, Carson WE, Roberts RD, Cripe TP. Ringwalt EM, et al. bioRxiv [Preprint]. 2024 Mar 3:2024.03.02.582994. doi: 10.1101/2024.03.02.582994. bioRxiv. 2024. PMID: 38464161 Free PMC article. Preprint.